Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapitinib + Paclitaxel in Advanced Breast Cancer (THYME)
NCT00900627Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in breast cancer and solid tumor comparing Sapitinib + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoints: Dose Limiting Toxicities and Progression-Free Survival up to 3 years. Started Jun 2009; status: completed.
02
Drugs
sapitinib
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT00900627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00900627.